Developing tests to detect and identify drug-resistant infections
TASK AREA B: NIAID Preclinical Services for AMR Diagnostics Development
['FUNDING_OTHER'] · DYNPORT VACCINE COMPANY, LLC · NIH-10913006
This study is working on better tests to quickly and accurately find drug-resistant bacteria in people, so patients can get the right treatment faster and more effectively.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DYNPORT VACCINE COMPANY, LLC (nih funded) |
| Locations | 1 site (FREDERICK, UNITED STATES) |
| Trial ID | NIH-10913006 on ClinicalTrials.gov |
What this research studies
This research focuses on creating and improving diagnostic tests that can accurately detect and identify drug-resistant bacteria in humans. By utilizing advanced biological assays, the project aims to enhance the ability to diagnose infections caused by Gram-negative bacteria, which are often resistant to standard treatments. Patients may benefit from more effective and timely diagnoses, leading to better-targeted therapies. The research involves collaboration with various laboratories and healthcare providers to ensure the tests meet clinical needs.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have infections caused by Gram-negative bacteria, particularly those that are resistant to antibiotics.
Not a fit: Patients with infections caused by non-Gram-negative bacteria or those who do not have drug-resistant infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and rapid diagnostic tests for drug-resistant infections, improving treatment outcomes for patients.
How similar studies have performed: Other research has shown success in developing diagnostic tests for infectious diseases, indicating that this approach has potential for impactful results.
Where this research is happening
FREDERICK, UNITED STATES
- DYNPORT VACCINE COMPANY, LLC — FREDERICK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KALLARKAL, ABRAHAM — DYNPORT VACCINE COMPANY, LLC
- Study coordinator: KALLARKAL, ABRAHAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.